PARADIGM BIO. ORDINARY (PAR) Short Interest
PARADIGM BIO. ORDINARY (ASX:PAR) had 0.00% of shares reported as short positions as of 16 July 2026, representing 5 shares. PARADIGM BIO. ORDINARY operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Paradigm Biopharmaceuticals Limited..
Paradigm Biopharmaceuticals is a late-stage drug development company with the mission to develop and commercialise pentosan polysulfate sodium for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, ageing, dege
Short position
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4PAR intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Latest PAR news
All newsAbout
website
address
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss PAR
Start a research thread or post the first pulse update